Capital Research Global Investors Buys 721,154 Shares of Cellebrite DI Ltd. $CLBT

Capital Research Global Investors grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 42.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,425,736 shares of the company’s stock after purchasing an additional 721,154 shares during the quarter. Capital Research Global Investors’ holdings in Cellebrite DI were worth $44,949,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Financial Management Professionals Inc. acquired a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $28,000. CWM LLC increased its holdings in Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after buying an additional 720 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares in the last quarter. Toth Financial Advisory Corp bought a new stake in Cellebrite DI during the third quarter worth $38,000. Finally, Pacer Advisors Inc. lifted its stake in Cellebrite DI by 523.4% in the third quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock valued at $51,000 after acquiring an additional 2,303 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of CLBT opened at $14.53 on Friday. The company’s 50-day moving average is $15.34 and its 200-day moving average is $16.91. The firm has a market capitalization of $3.62 billion, a PE ratio of 46.87, a PEG ratio of 2.22 and a beta of 1.30. Cellebrite DI Ltd. has a fifty-two week low of $11.76 and a fifty-two week high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, hitting the consensus estimate of $0.14. The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. Cellebrite DI’s revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 EPS. Analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Wall Street Zen downgraded Cellebrite DI from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Bank of America upped their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and an average price target of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.